Lewis Tanya
- SEC CIK
- 0001451038
No open-market purchases or sales filed in the past year.
Current role at each company
- DMAC DiaMedica Therapeutics Inc.Directoras of Jun 3, 2026
- REPL Replimune Group, Inc.Chief Dev. Op. Officeras of Jun 15, 2023
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Lewis Tanya as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
REPL Replimune Group, Inc.
Chief Dev. Op. Officer3 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 15, 2023 (view filing) | Jun 13 | 2 days | Lewis TanyaChief Dev. Op. Officer | SSale | −12.9K | $24.06 | −$309.4K | −8.7%135.3K after | 2 lots10b5-1 |
| May 18, 2023 (view filing) | May 16 | 2 days | Lewis TanyaChief Dev. Op. Officer | SSale | −12.2K | $18.05 | −$220.3K | −7.6%148.2K after | |
| May 18, 2022 (view filing) | May 16 | 2 days | Lewis TanyaChief Dev. Op Officer | SSale | −5.47K | $14.59 | −$79.9K | −4.3%120.4K after |